Clive Meanwell, chairman of investment firm Population Health Partners, was an AI skeptic until recently, according to an interview with STAT News. He now considers artificial intelligence a catalyst for biotech innovation.
The shift reflects a broader reassessment of AI's role in drug discovery and population health. Meanwell leads a firm focused on designing biotechs for large-scale health outcomes.
No specific numbers or details about investments or portfolio changes were disclosed in the interview. The article did not cite concrete examples of AI applications Meanwell now supports.
It remains unclear whether this change in perspective will translate into new investments from Population Health Partners. Meanwell's pivot could signal a strategic direction for the firm.
The interview offers a personal narrative of technological conversion rather than a detailed analysis of AI's impact on biotech. No independent data or opposing views were included in the source.